The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections
Open accessAbstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and chronic liver disease worldwide. Over the past decades many immunological studies defined host immune responses that mediate spontaneous clearance of acute HBV and HCV infection. However, host immune responses are also relevant in the context of treatment‐induced clearance of chronic HBV and HCV infection. First, the pretreatment level of interferon‐stimulated genes as well as genetic determinants of innate immune responses, such as single nucleotide polymorphisms near the IFNL3 gene, are strong predictors of the response to interferon‐alpha (IFN‐α)‐based therapy. Second, IFN‐α, which has been a mainstay of HBV and HCV therapy over decades, and ribavirin, which has also been included in interferon‐free direct antiviral therapy for HCV, modulate host immune responses. Third, both IFN‐α‐based and IFN‐α‐free treatment regimens of HBV and HCV infection alter the short‐term and long‐term adaptive immune response against these viruses. Finally, treatment studies have not just improved the clinical outcomes, but also provided opportunities to study virus‐host interaction. This review summarizes our current knowledge on how a patient's immune response affects the treatment outcome of HBV and HCV infection and how innate and adaptive immune responses themselves are altered by the different treatment regimens. ( H epatology 2015;61:712‐721)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552 · cited 1×
“This is because the transcriptional template of the virus, the covalently closed circular DNA (cccDNA), persists in the form of a minichromosome in host cells.(3) Immunosuppression, e.”
Background
Cited by
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Immune responses and immunopathology in acute and chronic viral hepatitis
Shin, E.-C., Sung, P. S., & Park, S.-H. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.69 · Cited by 365
An Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
MHC-E–Restricted CD8+ T Cells Target Hepatitis B Virus–Infected Human Hepatocytes
Burwitz, B. J., Hashiguchi, P. K., Mansouri, M., Meyer, C., Gilbride, R. M., Biswas, S., Womack, J. L., Reed, J. S., Wu, H. L., Axthelm, M. K., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900795 · Cited by 24
Metadata
- Authors
- Rehermann, B., & Bertoletti, A.
- Venue
- Hepatology
- Published
- 2015-01-20
- Volume
- 61
- Issue
- 2
- Pages
- 712-721
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2152543398
- Cited by
- 168
- References
- 3
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. https://app.cochat.ai/papers/10.1002/hep.27323
- The paper
- Rehermann, B., & Bertoletti, A. (2015). Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology. https://doi.org/10.1002/hep.27323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.